Multiple sclerosis (MS) is a chronic complex malady of the central nervous system (CNS) characterized by inflammation, demyelination, and neurodegeneration, resulting in a progressively increasing disability. With the only exceptions of ocrelizumab and siponimod, which have a moderate effect on disease progression, none of the 17 currently available drugs are able to halt or at least slow the relentless neuronal disability. Indeed, current therapies, focused primarily on pathological immune responses (i.e., immunomodulation and immunosuppression), are generally less effective in the progressive forms of the disease than in the relapsing remitting ones. Therefore, curing demyelination and the concomitant neurodegeneration, in addition to immunomodulation, needs to be addressed for a truly curative effect in all patients.

Developing such treatment is not an easy task, as it involves targeting complex pathological cascades in different brain cell types. Therefore, while monotherapies may be inappropriate, multipronged approaches will likely be needed to support the wide range of CNS functions and minimize injury and toxicity involving neurons, oligodendrocytes, and microglia.

On this basis, we were motivated to develop a polypharmacological treatment able not only to modulate immunomodulatory/inflammatory aspects of the disease, but also to counteract neurodegeneration and demyelination and to sustain remyelination.

We have contributed to the implementation of polypharmacology in the field of neurodegenerative drug discovery. In this project, we aimed to harness this knowledge to develop new polypharmacological tools that deliberately hit multiple biological targets (i.e., inflammation, neurodegeneration, demyelination/remyelination) in different brain cell types. To note, although combination therapy has been advocated and tested in the clinics for MS, to the best of our knowledge, no polypharmacological approach based on a single pharmaceutical ingredient, has been reported so far.

To do so, we turned our attention to the development of versatile polypharmacological tools, i.e., codrugs. "Codrugs" or "mutual prodrugs" are single molecules obtained by the conjugation of two therapeutic compounds with synergistic activity, via a cleavable linker. A marketed example is the antibacterial sultamicillin, an ampicillin/sulbactam codrug (Figure S1). The fact that the two starting compounds, following metabolic transformation, have the potential to be released in the same target cells and at the same time is a peculiar feature of codrugs with respect to combinations (two
that starting from a marketed drug (VPA) and an omega-3 polyunsaturated fatty acid food supplement (ALA) could mitigate the risk of toxicity for use in humans, thereby potentially expediting the clinical translation of eventual candidates.

Our strategy was founded upon the reported beneficial effects of ALA and VPA in MS. Several studies have demonstrated that ALA supplementation delays onset and reduces demyelination and cognitive dysfunction in the experimental autoimmune encephalomyelitis (EAE) model. These positive effects are accompanied by a shift in microglial polarization toward the beneficial M2 phenotype. In addition, higher levels of ALA were associated with lower disease activity.

Similarly, VPA has been shown to be effective in animal models of the disease. VPA, used for the treatment of neurological disorders for more than 40 years, exerts its beneficial effects through multiple mechanisms. Among them, which include GABA, glutamate receptor and sodium voltage-gated channel modulation, its activity as a histone deacetylase (HDAC) inhibitor has recently come to light. As an HDAC inhibitor, VPA is reported to be neuroprotective and neuroregenerative in various neurological diseases, including MS (although some controversy does exist).

Thus, we embarked on the development of ALA-VPA codrugs for MS. We deemed that such a concerted, simultaneous modulation of multiple critical pathways by VPA and ALA can result in a truly immunomodulatory, neuroprotective, and neurorestorative effect.

**Design.** The codrug strategy was based on a set of linkers (ethylene glycol, ethanolamine, and ethylenediamine) that allowed VPA and ALA to be covalently joined via their carboxylic acid functions. This linker strategy has been recently validated by the development of edasalonexent, a conjugate of salicylic acid and docosahexaenoic acid (DHA), currently clinically evaluated to treat Duchenne muscular dystrophy. The linking strategy allowed the formation of ester or amide bonds between the acid functions of VPA and ALA, obtaining conjugates 1–4 (Figure 2).

**Figure 1.** Chemical structures of α-linolenic acid, docosahexaenoic acid, edasalonexent, valproic acid, and salicylic acid.

**Figure 2.** Design of ALA-VPA conjugates 1–4.

On the basis of previous studies, we expected 1–4 to be stable in the circulation at different extents, depending on the nature of the formed bonds (amide vs ester). Then, hydrolysis should occur in the brain tissues where specific enzymes able to hydrolyze endogenous fatty acid conjugates are present. As reported for edasalonexent and a fatty acid cysteamine conjugate, the metabolism of 1–4 might be mediated by endocannabinoid metabolic enzymes, including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase, and N-acylethanolamine acid amidase. Then, each released starting framework (VPA or ALA) should maintain the ability to recognize its specific targets and, collectively, to produce multiple, synergistic pharmacological effects. In principle, the same effects could be also reached by a combination treatment of VPA and ALA. However, according to the previous reports, the herein proposed single-molecule conjugates might have advantages with respect to a classical drug combination: VPA and omega-3 FAs have the potential to be delivered in the target cells at the same time and in equimolar concentrations. Since multiple biological pathways in multiple brain cell types might be simultaneously hit, it is feasible to hypothesize that the resulting polypharmacology of 1–4 could be peculiar and not be replicated by administering VPA and ALA in combination, where each one has an individual ADME (absorption, distribution, metabolism and excretion) profile.

In the following, the synthesis, preliminary pharmacokinetic evaluation, and biological characterization of 1–4 at a cellular level are reported. We believe that, at this initial stage, cell-based systems maintain a reasonable screening efficiency while preserving network interactions, critical in a polypharmacology context.

**Chemistry.** For the synthesis of conjugates 1–4, a linear synthetic strategy based on 1-ethyl-3-(3-(dimethylamino)-propyl)carbodiimide (EDC)/4-dimethylaminopyridine (DMAP) coupling and protection/deprotection steps was followed (Scheme 1). First, the three bifunctional linkers, i.e., ethylene glycol, ethanolamine, and ethylenediamine, were monoprotected with the suitable protecting group to allow selective reaction on the proper function.

Standard reactions with di-tert-butyl decarbonate (Boc2O) or tert-butyldimethylsilyl chloride (TBSCI) provided the N-Boc- or the O-TBS-protected linkers 5–8 in very good yields (87–98%). Monoprotected 5–8 were then coupled with VPA after activation with EDC/DMAP to provide ester or amide intermediates 9–12, in moderate to good yields (42–68%). Treatment with trifluoroacetic acid (TFA) or tetrabutylammonium fluoride (TBAF) removed the Boc- or TBS-protecting groups, respectively, providing intermediates 13–16 (89–98%). Both deprotection reactions were conducted under anhydrous conditions and at 0 °C, in order to avoid
In addition, both diamide oxidation side-reactions. nitrogen atmosphere and in the dark, in order to minimize however, in this case, the reaction was carried out under μ concentrations (5, 10, 25, 50 μM) of each conjugate and plasma remaining fraction of the mean ± SE of at least 3 independent experiments, each run in triplicate. p < 0.001 compared to control conditions (0 μM), Student’s t test.

Table 1. Effect of 1–4 and Parent Compounds VPA and ALA on Cell Survival/Death in CGNs, As Determined by MTT Assay after 24 h Treatment

| compd   | 0 [μM] | 5 [μM] | 10 [μM] | 25 [μM] | 50 [μM] |
|---------|--------|--------|---------|---------|---------|
| VPA     | 100 ± 6| 100 ± 15| 106 ± 3 | 85 ± 14 | 97 ± 17 |
| ALA     | 100 ± 6| 93 ± 13 | 97 ± 3  | 79 ± 12 | 45 ± 5***|
| 1       | 100 ± 6| 98 ± 18 | 107 ± 3 | 89 ± 14 | 99 ± 15 |
| 2       | 100 ± 6| 97 ± 16 | 110 ± 3 | 96 ± 15 | 85 ± 14 |
| 3       | 100 ± 6| 119 ± 17| 116 ± 3 | 99 ± 17 | 41 ± 5***|
| 4       | 100 ± 6| 118 ± 16| 114 ± 3 | 71 ± 8  | 45 ± 5***|

Results are expressed as percentages of controls and are the mean ± SE of at least 3 independent experiments, each run in triplicate. p < 0.001 compared to control conditions (0 μM), Student’s t test.

stable for more than 85% after 1 h of incubation at 37 °C in rat plasma. Specifically, the percentage of diamide 1 remaining upon incubation is higher than that of ester/amide 2 (89% for 1 and 85% for 2). The mean plasma remaining fraction of the two conjugates after 1 h of incubation was compared by means of t test and a statistically relevant difference (p < 0.01) was observed.

In Vitro BBB Permeation Assay. In parallel, we tested 1 and 2 in the blood-brain barrier (BBB) specific parallel artificial membrane permeation assay (PAMPA-BBB) (Table 2). Both compounds were predicted to be BBB-permeable. Conjugate 1 had an effective permeability (P_e) of 27.98, which placed it in

| compd | P_e ± SEM (×10^−6 cm s⁻¹) | CNS (+/−) |
|-------|---------------------------|-----------|
| 1     | 27.98 ± 5.30              | CNS +     |
| 2     | 14.59 ± 1.61              | CNS +     |
| furosemide | 0.19 ± 0.07              | CNS −     |
| ranitidine | 0.35 ± 0.31              | CNS −     |
| donepezil | 21.93 ± 2.06             | CNS +     |
| tacrine | 5.96 ± 0.59               | CNS +     |

P_e ± SEM (n = 3). Each compound was assessed in quadruplicate.

“Reagents and conditions: (i) TBSCI, imidazole, DCM, r.t., 24 h; (ii) Boc₂O, DCM, r.t., 24 h. (iii) EDC, DMAP, DCM, r.t., 8 h, N₂; (iv) TFA, DCM, r.t., 2 h; (v) TBAF, r.t., 24 h; (vi) ALA, EDC, DMAP, DCM, r.t., 8 h, N₂.

concomitant VPA hydrolysis. Finally, targets 1–4 were synthesized from ALA and the respective VPA-functionalized linker (13–16), using the previous EDC/DMAP protocol. However, in this case, the reaction was carried out under nitrogen atmosphere and in the dark, in order to minimize oxidation side-reactions.

Neuro- and Hepatotoxicity Assays. A preliminary cytotoxicity screening was performed on conjugates 1–4 using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Tables 1 and S1). Increasing

From Table 1, it is evident that diamide 1 and ethanolamide 2 display a low neurotoxicity profile, and also at the higher tested concentrations (viability > 85% at 50 μM). They are less toxic compared to the inverse ethanolamide (3, 41% viability) and diester (4, 45%) analogues and also to reference compounds. Notably, while the CNS drug VPA shows negligible neurotoxicity, ALA is neurotoxic at 50 μM (45%). In addition, both diamide 1 and ethanolamide 2 showed a low hepatotoxicity, even at the higher tested concentrations (viability > 80% at 25 μM; Table S1). Hence, we selected 1 and 2 for further studies, because they are representative of two different linker types and are the less toxic ones among the synthesized set, especially at the more therapeutically relevant concentrations (5 and 10 μM).

Plasma Stability Assay. Our aim was to develop plasmastable conjugates that would be hydrolyzed in the brain. Selective localized hydrolysis of conjugates 1 and 2 would permit a CNS-targeted profile and less side effects. Thus, plasma stability is an important pharmacokinetic prerequisite for 1 and 2. As reported by stability assays performed by LC-DAD-MS/MS analysis (Figure 3), conjugates 1 and 2 are

Figure 3. Rat plasma stability of conjugates 1 and 2 at 37 °C: percentage remaining upon incubation, assessed by means of LC-DAD-MS/MS. Analyses were performed in triplicate.

Table 2. PAMPA Effective Permeability (P_e) Values with Related Predictive BBB Penetrations of Commercial Drugs, 1 and 2

| compd | P_e ± SEM (×10^−6 cm s⁻¹) | CNS (+/−) |
|-------|---------------------------|-----------|
| 1     | 27.98 ± 5.30              | CNS +     |
| 2     | 14.59 ± 1.61              | CNS +     |
| furosemide | 0.19 ± 0.07              | CNS −     |
| ranitidine | 0.35 ± 0.31              | CNS −     |
| donepezil | 21.93 ± 2.06             | CNS +     |
| tacrine | 5.96 ± 0.59               | CNS +     |

P_e ± SEM (n = 3). Each compound was assessed in quadruplicate.

References:
1. From Table 1, it is evident that diamide 1 and ethanolamide 2 display a low neurotoxicity profile, and also at the higher tested concentrations (viability > 85% at 50 μM). They are less toxic compared to the inverse ethanolamide (3, 41% viability) and diester (4, 45%) analogues and also to reference compounds. Notably, while the CNS drug VPA shows negligible neurotoxicity, ALA is neurotoxic at 50 μM (45%). In addition, both diamide 1 and ethanolamide 2 showed a low hepatotoxicity, even at the higher tested concentrations (viability > 80% at 25 μM; Table S1). Hence, we selected 1 and 2 for further studies, because they are representative of two different linker types and are the less toxic ones among the synthesized set, especially at the more therapeutically relevant concentrations (5 and 10 μM).

Plasma Stability Assay. Our aim was to develop plasmastable conjugates that would be hydrolyzed in the brain. Selective localized hydrolysis of conjugates 1 and 2 would permit a CNS-targeted profile and less side effects. Thus, plasma stability is an important pharmacokinetic prerequisite for 1 and 2. As reported by stability assays performed by LC-DAD-MS/MS analysis (Figure 3), conjugates 1 and 2 are

Figure 3. Rat plasma stability of conjugates 1 and 2 at 37 °C: percentage remaining upon incubation, assessed by means of LC-DAD-MS/MS. Analyses were performed in triplicate.

Table 2. PAMPA Effective Permeability (P_e) Values with Related Predictive BBB Penetrations of Commercial Drugs, 1 and 2

| compd | P_e ± SEM (×10^−6 cm s⁻¹) | CNS (+/−) |
|-------|---------------------------|-----------|
| 1     | 27.98 ± 5.30              | CNS +     |
| 2     | 14.59 ± 1.61              | CNS +     |
| furosemide | 0.19 ± 0.07              | CNS −     |
| ranitidine | 0.35 ± 0.31              | CNS −     |
| donepezil | 21.93 ± 2.06             | CNS +     |
| tacrine | 5.96 ± 0.59               | CNS +     |

P_e ± SEM (n = 3). Each compound was assessed in quadruplicate.
the high BBB permeability category (Table 2), higher than that of two CNS drugs (donepezil and tacrine).

**Brain Stability Assay.** We anticipated that, once they entered into the brain, conjugates would be hydrolyzed to the individual components by intracellular metabolic enzymes processing fatty acid derivatives (e.g., FAAH).

Thus, the stability of 1 and 2 was evaluated by LC-DAD-MS/MS analysis of rat brain homogenate incubated with the conjugates, which was sampled at regular intervals over 1 h. To obtain initial clues on the implication of FAAH enzymes in hydrolysis, the assays were performed in the absence and presence of 5 μM FAAH inhibitor PF-3845.

As shown in Figure 4, both conjugates undergo metabolism (i.e., total disappearance of starting compound) within 1 h of incubation, with a more marked decrease rate with regard to ethanolamide 2 (half-life of about 16 min) compared to diamide 1 (half-life of about 23 min). Moreover, we can infer that the observed hydrolysis is FAAH-dependent, as the addition of PF-3845 blocks the hydrolysis of both 1 and 2 to a large extent. To note, although it appears that the plasma stability of these codrugs is higher than that in rat brain homogenates, we cannot exclude that hydrolytic reactions might occur in tissues like the liver.

After getting a preliminary indication that conjugates 1 and 2 would be metabolized to afford the parent compounds selectively in brain target cells, we investigated the biological effects that they could induce.

**HDAC Assays.** Several studies have shown that long-term administration of VPA results in regulation of inflammatory processes, neuroprotection, and cell differentiation through HDAC inhibition.20,21 Thus, we preliminarily verified whether 1 and 2 would retain the HDAC inhibitory capacity of the parent VPA in human medulloblastoma cell line DAOY (Figure 5). VPA is a relatively weak HDAC inhibitor, with millimolar activity (a clinically achievable concentration).22 Thus, we tested it in the 0.1–1.5 mM range.

As expected, VPA treatment induced a strong inhibition of HDAC, shown by a significant, concentration-dependent increment in acetylation levels of histone H3 (Figure 5, left panel). Remarkably, a similar increase of H3 acetylation was detected in neuronal cells exposed to conjugates 1 and 2 at 0.5 mM (Figure 5, right panel).

**Immunomodulation Assays.** Microglia, essential regulators of neuroinflammatory processes, can be polarized to two distinct activation states: M1 and M2. M1 microglia have proinflammatory, neurotoxic properties and are modeled in vitro through lipopolysaccharides (LPS) activation. Alternatively, M2 microglia are involved in anti-inflammatory processes, contributing to trophic support of neurons and neuroprotective functions. A marked microglial activation with high expression levels of proinflammatory genes is found in MS lesions.23 Conversely, the neuroprotective effects of the MS drug glatiramer are mediated by activated M2 microglia.24 To this end, we evaluated whether 1 and 2 modulate microglial shift from an M1 neurotoxic phenotype to an M2 neuroprotective one. Therefore, N9 microglial cells were treated with 100 ng/mL LPS in the presence or absence of increasing concentrations (0.5, 1.5, 10 μM) of 1, 2, parent compounds VPA and ALA, as well as and their 1:1 combination (ALA+VPA, Figure 6). After pretreatment for 6 h and administration for a further 24 h, the microglial phenotype was evaluated through Western blot analysis of the M1-iNOS (inducible Nitric Oxide Synthase) and M2-TREM2 (Triggering Receptor Expressed on Myeloid cells 2) markers (Figure 6). We also assessed nitrite production, due to iNOS induction, in the incubation media.

As reported in Figure 6, compounds 1 and 2, even at low concentration (0.5 μM), significantly decrease microglia production of the M1 proinflammatory marker iNOS, at an extent similar to that of parent compounds. Remarkably, they were more effective than the ALA+VPA combination. Interestingly, 1 and 2 display immunomodulatory properties, as revealed by the unchanged expression of TREM2 (M2 marker). This is important, as TREM2 is reported to invoke microglia to phagocytose myelin debris in MS lesions25 and its blockade results in an amplified demyelination in EAE.26 Regarding the levels of nitrites, 1 and 2 reduced their concentration more effectively than VPA and similarly to the ALA+VPA combination.

**Oli-Neu Cell Cytotoxicity Assays.** Oligodendrocytes are the myelin-forming cells. They are the end product of a cell lineage which, following finely tuned cycles of proliferation, migration, and differentiation, finally produces myelin.27 The
inhibitory microenvironment in MS lesions abolishes the expansion and differentiation of resident oligodendrocyte precursor cells (OPCs) into mature myelin-forming oligodendrocytes. Loss of myelin, in turn, accounts for motor and cognitive deficits in MS patients. Thus, chemical manipulation of OPC fate may open new avenues for regenerative therapies in MS.

Here, we used Oli-neu cells, an oligodendroglial precursor cell line, as an accepted in vitro model to screen the remyelination potential of our molecules. First, we tested the toxicity of our conjugates and parent compounds against Oli-Neu. After treatment with increasing concentrations (1−10 μM) for 24 h, the MTT assay shows that, while VPA and ALA decrease cell viability already at 1 μM, conjugates 1 and 2 show no toxicity even at the higher concentrations (10 μM). Intriguingly, cells treated with ethanolamide 2 revealed a significantly higher metabolic activity (MTT readout) compared with control cells (Table 3).

**Oli-Neu Cell Proliferation and Differentiation Assay.** OPC proliferation and migration to the CNS injury site as well as their differentiation are critical steps toward remyelination in MS. HDAC activity plays a crucial role in OPC proliferation/differentiation; therefore, HDAC modulation is widely considered a promising therapeutic target for MS. Accordingly, VPA has been shown to increase myelin repair in the EAE model, by acting on OPC recruitment. Therefore, we tested the effect of our compounds on OPC proliferation and differentiation, through cell counting, measure of filaments, and analysis of proliferation/differentiation markers (Figure 7).

Table 3. Effect of 1 and 2 on Cell Survival/Death through MTT Assay in Oli-Neu Cells (Immortalized Mouse Oligodendrocyte Precursor Cells), in Comparison with Parent Compounds ALA and VPA

| compd     | 0 [μM] | 0.5 [μM] | 1 [μM] | 5 [μM] | 10 [μM] |
|-----------|--------|----------|--------|--------|---------|
| VPA       | 100 ± 6| 75 ± 7**b| 72 ± 6**b| 74 ± 9**b| 76 ± 7**b|
| ALA       | 100 ± 6| 78 ± 5**b| 75 ± 9 | 71 ± 8**b| 68 ± 6**b|
| 1         | 100 ± 6| 89 ± 9   | 95 ± 8 | 88 ± 5**b| 93 ± 6**b|
| 2         | 100 ± 6| 110 ± 4  | 115 ± 7**b| 105 ± 8| 101 ± 8|

*Results are expressed as percentages of controls and are the mean ± SE of at least 2 independent experiments. b**p < 0.01. c*p < 0.05 compared to control conditions (0 μM), one way-ANOVA followed by Bonferroni’s posthoc test.
While Oli-Neu cells treated with VPA+ALA show a significant increase in the cell number, with a parallel decrease in the filament length, compound 1 and 2, similarly to VPA, decrease cell number with a parallel increase in filament length. This suggests that 1 and 2 might induce OPCs differentiation to oligodendrocytes. To further support this hypothesis, Western blot analysis showed a marked decrease in the expression of Olig2, a marker of OPCs proliferation, for 1, 2 and VPA, but not for ALA and ALA+VPA. This profile was paralleled by a significant increase in the expression of CNPase, a marker of differentiation, for both 1 and VPA. Collectively, these data point to an induction of OPC differentiation toward oligodendrocytes by 1 and 2, which, similarly to VPA, can perform myelination/remyelination. Importantly, this behavior is not shown by ALA and neither by ALA+VPA combination but is peculiar to conjugate 1.

Neuroprotection Assay. Several lines of evidence point to MS as not only an inflammatory but also a neurodegenerative disease. Thus, neuroprotective agents may hold promise for MS therapy.\(^1\) \(^2\) VPA has been reported to exert neuroprotective effects and to reduce glutamatergic excitatory neurotransmission.\(^\text{33}\) Thus, to test the neuroprotective capability of 1 and 2, we used a glutamate excitotoxicity model of primary cortical neurons. At day 8 in vitro (8 DIV), CGNs were pretreated with the compounds for 6 h, before adding 100 \(\mu\)M glutamate/10 \(\mu\)M glycine insult for further 24 h. As illustrated in Figure 8, pretreatment with 1 resulted a more neuroprotective against glutamatergic excitotoxicity when compared with VPA, ALA VPA+ALA 1:1, and 2, especially at lower concentrations (5 and 10 \(\mu\)M). Furthermore, while reference compounds (alone and in combination) increase glutamate/glycine excitotoxicity at higher doses, 1 was not toxic even at the highest concentration tested (25 \(\mu\)M).

CONCLUSIONS

Although significant progress has been made in developing immunomodulatory treatments, there is a lack of therapeutic options that address the multiple, concomitant pathophysiological aspects of MS. This study, albeit very preliminary, demonstrates for the first time the potential of VPA/ALA codrugs to achieve polypharmacology in MS. Particularly, diamide conjugate 1 displays an overall immunomodulatory, remyelinating, and neuroprotective profile that is superior to that of the parent compounds, as well as to their equimolar combination. The collected results, the experience gained from the use of VPA in humans for over 40 years, and the fact that ALA is a natural product present in many foods might warrant further investigation into this series. In parallel, the fact that a recent study has highlighted a dampened remyelination and a decreased oligodendrocyte cell count for VPA\(^\text{34}\) and its use in MS therapy is still controversial\(^\text{15}\) suggests that other conjugations of promising compounds should be explored.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00375.

Experimental details for chemistry and biological assays, cell toxicity plots, NMR spectra, LC-MS/MS chromatograms and MS spectra for compounds 1 and 2 (PDF)

AUTHOR INFORMATION

Corresponding Author

Maria Laura Bolognesi − Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy; orcid.org/0000-0002-1289-5361; Email: marialaura.bolognesi@unibo.it

Authors

Michele Rossi − Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy
Sabrina Petralia − Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy
Michele Protti − Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy
Monica Baiula − Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy
Tereza Kobrlova − Biomedical Research Center, University Hospital, CZ-500 05 Hradec Kralove, Czech Republic
Ondrej Soukup − Biomedical Research Center, University Hospital, CZ-500 05 Hradec Kralove, Czech Republic
Santi Mario Spampinato − Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy
Laura Mercolini − Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy
Barbara Monti − Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, I-40126 Bologna, Italy

Complete contact information is available at: https://pubs.acs.org/10.1021/acsmedchemlett.0c00375

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Author Contributions

M.R. and S.P. equally contributed to this work.
Funding
This work was supported by the University of Bologna (Grant RFO 2016). M.R. acknowledges the Emilia Romagna regional Ph.D. program “Piano triennale Alte competenze per la ricerca, il trasferimento tecnologico e l’imprenditorialità” (Ph.D. fellow 2016–2019). O.S and T.K. acknowledge the University Hospital Hradec Kralove (MH CZ-DRO) (UHKK,00179906) and (CZ.02.1.01.0/0.0/0.0/18_069/72.
ACS Med. Chem. Lett. Acid Conjugates of Niacin and Salicylic Acid. Zimmer, M.; Jirousek, M. R. Synthesis and Characterization of Fatty D.; Shoelson, A.; Smith, J.; Ting, A.; Wensley, A.; Yeager, M.; combat neurodegenerative diseases.

V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to scleroderma. Correale, J.; Gaitás, L.; Baldini, E.; Baldin, E.; Muratori, L.; De Ponti, F.; Raschi, E. Liver injury with

ABBREVIATIONS
ALAA, α-linolenic acid; BBBC, brain-blood barrier; CGNs, cerebellar granule neurons; CNS, central nervous system; DHA, acid docosahexaenoic acid; DMAP, 4-dimethylamino- acid thromboxane; TFA, trifluoroacetic acid; TREM2, triggering receptor

REFERENCES
(1) Filippini, M.; Bar-Or, A.; Piehl, F.; Preziosio, P.; Solarli, A.; Vukusic, S.; Rocca, M. A. Multiple sclerosis. Nat. Rev. Dis Primers 2018, 4 (1), 43.
(2) Correale, J.; Gattán, M. I.; Ysrraelit, M. C.; Fiol, M. P. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 2017, 140 (3), 527–546.
(3) Melchor, G. S.; Khan, T.; Reger, J. F.; Huang, J. K. Remyelination Pharmacotherapy Investigations Highlight Diverse Mechanisms Underlying Multiple Sclerosis Progression. ACS Pharmacol Trans Sci. 2019, 2 (6), 372–386.
(4) Conway, D.; Cohen, J. A. Combination therapy in multiple sclerosis. Lancet Neurol. 2010, 9 (3), 299–308.
(5) Cavalli, A.; Bolognesi, M. I.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51 (3), 347–72.
(6) Bolognesi, M. L. Harnessing Polypharmacology with Medicinal Chemistry. ACS Med. Chem. Lett. 2019, 10 (3), 273–275.
(7) Albertini, C.; Salerno, A.; de Sena Murteira Pinheiro, P.; Bolognesi, M. L. From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology. Med. Res. Rev. 2020, DOI: 10.1002/med.21699.
(8) Das, N.; Dhanawat, M.; Dash, B.; Nagarwal, R. C.; Shrivastava, S. K. Codrug: an efficient approach for drug optimization. Eur. J. Pharm. Sci. 2010, 41 (5), 571–88.
(9) Yu, C. B.; Bemis, J. E.; Benson, E.; Bista, P.; Carney, D. F.; Fahner, R.; Lee, D.; Liu, F.; Lonkar, P.; Milone, J. C.; Nichols, A. J.; Picarella, D.; Shoelson, A.; Smith, J.; Ting, A.; Wensley, A.; Yeager, M.; Zimmer, M.; Jrousek, M. R. Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid. J. Med. Chem. 2016, 59 (3), 1217–31.
(10) Fornasari, E.; Di Stefano, A.; Cacciatore, I. Direct-And Spacer-Coupled Codrug Strategies for the Treatment of Alzheimer’s Disease. Austin Alzheimers J. Parkinsons Dis 2014, 1 (2), 9.
(11) Mehta, L. R.; Dworkin, R. H.; Schwid, S. R. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat. Clin. Pract. Neurol. 2009, 5 (2), 82–92.
(12) Bjornevik, K.; Myhr, K. M.; Beiske, A.; Bjerve, K. S.; Holmøy, T.; Hovdal, H.; Midgard, R.; Røise, T.; Wergeland, S.; Torkildsen, O. α-linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Mult Scler 2019, 25 (7), 987–993.
(13) Lv, J.; Du, C.; Wei, W.; Wu, Z.; Zhao, G.; Li, Z.; Xie, X. The anti-epileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis. J. Biol. Chem. 2012, 287 (34), 28656–65.
(14) Monti, B.; Poluzzi, E.; Contestabile, A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr. Med. Pharmacol 2009, 2 (1), 95–109.
(15) Nielsen, N. M.; Svánström, H.; Stenager, E.; Magyari, M.; Koch-Henriksen, N.; Pasternak, B.; Hvid, A. The use of valproic acid and multiple sclerosis. Pharmacoepidemiol. Drug Saf. 2015, 24 (3), 262–8.
(16) Finanger, E.; Vandenborende, K.; Finkel, R. S.; Lee Sweeney, H.; Tennekoon, G.; yum, S.; Mancini, M.; Bista, P.; Nichols, A.; Liu, H.; Fretzen, A.; Donovan, J. M. Phase 1 Study of Edasalonexet (CAT-1004), an Oral NF-kB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy. J. Neuromusc Dis 2019, 6 (1), 43–54.
(17) Vu, C. B.; Bridges, R. J.; Pena-Rasgado, C.; Lacerda, A. E.; Bordwell, C.; Sewell, A.; Nichols, A. J.; Chandran, S.; Lonkar, P.; Picarella, D.; Tong, A.; Wensley, A.; Yeager, M.; Liu, F. Fatty Acid Cysteamin conjugates as novel and potent autophagy activators that enhance the correction of misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). J. Med. Chem. 2017, 60 (1), 458–473.
(18) Bagchi, S.; Chhibber, T.; Lahooti, B.; Verma, A.; Borse, V.; Jayant, R. D. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview. Drug Des., Dev. Ther. 2019, 13, 3591–3605.
(19) Antonazzo, I. C.; Poluzzi, E.; Forcise, E.; Riise, T.; Bjornevik, K.; Baldin, E.; Muratori, L.; De Ponti, F.; Raschi, E. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Mult Scler 2019, 25 (12), 1633–1640.
(20) Chen, S.; Wu, H.; Klebe, D.; Hong, Y.; Zhang, J. Valproic acid: a new candidate of therapeutic application for the acute central nervous system injuries. Neurochem. Res. 2014, 39 (9), 1621–33.
(21) Chen, J. Y.; Chu, L. W.; Cheng, K. I.; Hsieh, S. L.; Juan, Y. S.; Wu, B. N. Valproate reduces neuroinflammation and neuronal death in a rat chronic constriction injury model. Sci. Rep. 2018, 8 (1), 16457.
(22) Kim, H. J.; Bae, S. C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3 (2), 166–79.
(23) Wang, J.; Wang, J.; Wang, J.; Yang, B.; Weng, Q.; He, Q. Targeting microglia and macrophages: A Potential Treatment Strategy for Multiple Sclerosis. Front. Pharmacol. 2019, 10, 286.
(24) Ratchford, J. N.; Endres, C. J.; Hammoud, D. A.; Pomper, M. G.; Shiee, N.; McGready, J.; Pham, D. L.; Calabresi, P. A. Decreased microglial activation in MS patients treated with glatiramer acetate. J. Neurosci. 2012, 59 (6), 1199–205.
(25) Brendecke, S. M.; Prinz, M. Do not judge a cell by its cover—diversity of CNS resident, adjoining and infiltrating myeloid cells in and epigenetic mechanisms of valproic acid neuroprotection. Curr. Med. Pharmacol 2007, 37 (5), 591–605.
(26) Piccolo, L.; Buonsanti, C.; Mariani, M.; Celli, M.; Gifflann, S.; Cross, A. H.; Colonna, M.; Panina-Bordignon, P. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2007, 37 (5), 1290–301.
(27) Bradl, M.; Lassmann, H. Oligodendrocytes: biology and pathology. Acta Neuropathol. 2010, 119 (1), 37–53.
(28) Franklin, R. J. M.; Ffrench-Constant, C. Regenerating CNS myelin - from mechanisms to experimental medicines. Nat. Rev. Neurosci. 2017, 18 (12), 753–769.
(29) Kipp, M.; van der Star, B.; Vogel, D. Y.; Puentes, F.; van der Valk, P.; Baker, D.; Amor, S. Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Mult. Scler. Relat. Disord. 2012, 1 (1), 15–28.
(30) Skaper, S. D. Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases. Prog. Brain Res. 2019, 245, 119–144.
(31) Pazhoohan, S.; Satarian, L.; Asghari, A. A.; Salimi, M.; Kiani, S.; Mani, A. R.; Javan, M. Valproic Acid attenuates disease symptoms and increases endogenous myelin repair by recruiting neural stem cells and oligodendrocyte progenitors in experimental autoimmune encephalomyelitis. Neurodegener. Dis. 2014, 13 (1), 45–52.
(32) Maghzii, A. H.; Minagar, A.; Waubant, E. Neuroprotection in multiple sclerosis: a therapeutic approach. CNS Drugs 2013, 27 (10), 799–815.
(33) Zeise, M. L.; Kasparow, S.; Ziegglänsberger, W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 1991, 544 (2), 345–8.
(34) Hooijmans, C. R.; Hlavica, M.; Schuler, F. A. F.; Good, N.; Good, A.; Baumgartner, L.; Galeno, G.; Schneider, M. P.; Jung, T.; de Vries, R.; Ineichen, B. V. Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis. Sci. Rep. 2019, 9 (1), 822.